{
  "study_metadata": {
    "study_id": "NCT00823381",
    "design": "RCT"
  },
  "exposure": {
    "label": "resveratrol supplementation (75 mg/day)",
    "comparator": "placebo"
  },
  "outcomes": [
    {
      "name": "HOMA_IR",
      "timepoint_weeks": 12,
      "arm_name": "intervention",
      "n": 15,
      "baseline_mean": 1.41,
      "baseline_sd": 0.8,
      "followup_mean": 0.96,
      "followup_sd": 0.48,
      "units": null
    },
    {
      "name": "HOMA_IR",
      "timepoint_weeks": 12,
      "arm_name": "control",
      "n": 14,
      "baseline_mean": 1.17,
      "baseline_sd": 0.69,
      "followup_mean": 1.32,
      "followup_sd": 0.75,
      "units": null
    }
  ],
  "comment_detailed": "A 12‑week, double‑blind, placebo‑controlled RCT in 29 non‑obese postmenopausal women tested 75 mg/day resveratrol versus placebo. Baseline and 12‑week HOMA‑IR values were extracted from Table 2; no other glycemic outcomes were reported.",
  "missing_fields": [],
  "evidence": [
    "Table 2: \"HOMA-IR 1.17 ± 0.69\" (placebo baseline)",
    "Table 2: \"HOMA-IR 1.41 ± 0.80\" (resveratrol baseline)",
    "Table 2: \"HOMA-IR 1.32 ± 0.75\" (placebo 12‑wk)",
    "Table 2: \"HOMA-IR 0.96 ± 0.48\" (resveratrol 12‑wk)"
  ],
  "comment": "All key fields extracted with high confidence",
  "confidence": 0.9
}